These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19563324)

  • 1. Cholesterol-lowering therapy and the Australian Pharmaceutical Benefits Scheme: a population study.
    Adams RJ; Appleton S; Wilson DH; Taylor AW; Chittleborough C; Gill T; Ruffin RE
    Aust Health Rev; 2009 May; 33(2):325-33. PubMed ID: 19563324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population.
    Rodriguez F; Olufade TO; Ramey DR; Friedman HS; Navaratnam P; Heithoff K; Foody JM
    J Womens Health (Larchmt); 2016 Jul; 25(7):697-706. PubMed ID: 26889924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
    Forge BH; Briganti EM
    Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia.
    Luke JN; Brown A; O'Neal DN; O'Dea K; Jenkins AJ; Kelaher M; Best JD; Rowley KG
    Med J Aust; 2009 May; 190(10):552-6. PubMed ID: 19450200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme.
    Hajati F; Atlantis E; Bell KJL; Girosi F
    BMJ Open; 2018 Mar; 8(3):e019041. PubMed ID: 29523561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years].
    Malyutina SK; Mazdorova EV; Shapkina MY; Avdeeva EM; Simonova GI; Hubacek JA; Bobak M; Nikitin YP; Ryabikov AN
    Kardiologiia; 2021 Dec; 61(12):49-58. PubMed ID: 35057721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach.
    Gadowski AM; Nanayakkara N; Heritier S; Magliano DJ; Shaw JE; Curtis AJ; Zoungas S; Owen AJ
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf.
    Al-Rasadi K; Al-Zakwani I; Al Mahmeed W; Arafah M; Al-Hinai AT; Shehab A; Al Tamimi O; Alawadhi M
    Curr Med Res Opin; 2014 Dec; 30(12):2429-35. PubMed ID: 25222765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.
    Primatesta P; Poulter NR
    BMJ; 2000 Nov; 321(7272):1322-5. PubMed ID: 11090516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register.
    Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Andersson Sundell K; Eliasson B; Eeg-Olofsson K
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.
    Miller M; Byington R; Hunninghake D; Pitt B; Furberg CD
    Arch Intern Med; 2000 Feb; 160(3):343-7. PubMed ID: 10668836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Under-use of appropriate blood pressure-lowering and lipid-lowering therapy in the Busselton baby boomer population.
    Yiu W; Knuiman M; Wallace H; Hung J
    Aust J Gen Pract; 2019 Dec; 48(12):883-889. PubMed ID: 31774993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.